Sanofi US is voluntarily recalling all Auvi‑Q® (epinephrine injection, USP). The recall involves all Auvi‑Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. The products have been found to potentially have inaccurate dosage delivery.
Epinephrine is the first-line treatment for anaphylaxis, a severe allergic reaction that is rapid in onset and is potentially life-threatening. Because food allergy reactions can vary in severity and are unpredictable, it is critically important to carry two epinephrine auto-injectors at all times in order to have quick access to this life-saving medication. Information about patient assistance resources and training for different auto-injector options can be found at the following links: